US FDA approves Pfizers PARP inhibitor for metastatic breast cancer
US FDA approves Pfizer’s PARP inhibitor for metastatic breast cancer
The FDA approved Pfizerâs therapy for metastatic breast cancers, after clinical trials showed strong progression-free survival rates.
Original Article: US FDA approves Pfizer’s PARP inhibitor for metastatic breast cancer
More From BioPortfolio on "US FDA approves Pfizer’s PARP inhibitor for metastatic breast cancer"